—

Arrowhead designs RNAi medicines that silence disease-causing genes. Its TRiM platform lets it hit tissues beyond the liver — heart, muscle, lung, brain — and it turns that pipeline into cash two ways: it sells its first approved drug REDEMPLO (plozasiran) itself, and it licenses other programs to Amgen, Takeda, Sarepta, GSK and Novartis for upfronts, milestones and royalties. FY2025 revenue jumped to ~$829M on those deals plus its first FDA approval.

What Arrowhead Pharmaceuticals, Inc. really sells

Arrowhead designs RNAi medicines that silence disease-causing genes. Its TRiM platform lets it hit tissues beyond the liver — heart, muscle, lung, brain — and it turns that pipeline into cash two ways: it sells its first approved drug REDEMPLO (plozasiran) itself, and it licenses other programs to Amgen, Takeda, Sarepta, GSK and Novartis for upfronts, milestones and royalties. FY2025 revenue jumped to ~$829M on those deals plus its first FDA approval.

Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.

Why this rating?